CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement